SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Expands Sugemalimab Reach As Valuation Questions Linger
CStone Pharmaceuticals (SEHK:2616) has drawn fresh attention after signing an exclusive commercialization agreement with Arrotex Pharmaceuticals for its cancer drug sugemalimab in Australia and New Zealand. The deal includes a profit share structure.
See our latest analysis for CStone Pharmaceuticals.
CStone Pharmaceuticals' latest commercialization deal and recent insider share purchases come after a sharp 42.03% decline in the 90 day share price return. However, a 22.90% 7 day share price...